|
|
|
|
|
|
|
|
abstract:
Long-term survival of patients with mismatch repair-deficient, high-stage ovarian clear cell carcinoma
21 JUL 2016
Aims
Gynaecological
cancer patients with germline mutations appear to have a better
prognosis than those with sporadic malignancies. Following the
observation of long-term survival in a patient with stage III ovarian
clear cell carcinoma (CCC) and possible Lynch syndrome (LS), DNA
mismatch repair (MMR) protein immunohistochemistry was performed in a
series of high-stage CCC and correlated with patient outcomes.
Methods and Results
Thirty-two
consecutive cases of stage III/ IV ovarian CCCs accessioned between
1992 and 2015 were examined. The tumours from two patients (6%),
including the index case, showed loss of MSH2/MSH6 expression while
MLH1/PMS2 staining was retained. The index patient subsequently
developed colonic and rectal carcinomas that were also MSH2/MSH6
deficient while the second patient had a genetically confirmed germline
MSH2 mutation. All other tumours showed retained expression of the four
MMR proteins. The two patients with MMR protein-deficient tumours were
alive 160 months and 124 months following surgery whereas the median
survival of patients with MMR protein-intact CCCs was 11.8 months (75th and 25th percentiles of 8.1 months and 39.3 months, respectively), with 21 patients deceased due to tumour.
Conclusions
Larger studies are required but high-stage, MMR protein-deficient CCCs may have a relatively favourable prognosis.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.